Principal Financial Group Inc Cogent Biosciences, Inc. Transaction History

Principal Financial Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$6.01 - $9.04 $22,261 - $33,484	-3,704 Reduced 18.6%	16,211 $136,000
Q1 2024 Apr 29, 2024	SELL	$4.38 - $9.02 $998 - $2,056	-228 Reduced 1.13%	19,915 $133,000
Q4 2023 Feb 07, 2024	SELL	$4.06 - $10.08 $4,563 - $11,329	-1,124 Reduced 5.29%	20,143 $118,000
Q3 2023 Nov 02, 2023	BUY	$9.69 - $13.34 $27,161 - $37,392	2,803 Added 15.18%	21,267 $207,000
Q2 2023 Aug 07, 2023	BUY	$9.85 - $13.24 $13,583 - $18,257	1,379 Added 8.07%	18,464 $218,000
Q1 2023 May 09, 2023	BUY	$10.04 - $15.5 $25,150 - $38,827	2,505 Added 17.18%	17,085 $184,000
Q4 2022 Feb 09, 2023	BUY	$10.65 - $14.84 $155,277 - $216,367	14,580 New	14,580 $168,000

172

114M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $612M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.